5-bromo-furan-2-carboxylic acid ((S)-2-methyl-1-methylcarbamoyl-propyl)-amide | 1222809-29-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 5-bromo-furan-2-carboxylic acid ((S)-2-methyl-1-methylcarbamoyl-propyl)-amide
• 英文别名: 5-bromo-N-[(2S)-3-methyl-1-(methylamino)-1-oxobutan-2-yl]furan-2-carboxamide
• CAS: 1222809-29-1
• 化学式: C₁₁H₁₅BrN₂O₃
• 分子量: 303.156
• InChiKey: DYQKAJUWEAWWSO-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  71.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-bromo-furan-2-carboxylic acid ((S)-2-methyl-1-methylcarbamoyl-propyl)-amide 、 3-(N-BOC-氨甲基)苯基硼酸 在 二氯双[二叔丁基-(4-二甲基氨基苯基)膦]钯(II) 、 sodium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 tert-butyl (S)-(3-(5-((3-methyl-1-(methylamino)-1-oxobutan-2-yl)carbamoyl)furan-2-yl)benzyl)carbamate
  参考文献：
  名称：

  SAR studies of non-zinc-chelating MMP-13 inhibitors: Improving selectivity and metabolic stability

  摘要：

  SAR studies to improve the selectivity and metabolic stability of a class of recently discovered MMP-13 inhibitors are reported. Improved selectivity was achieved by modifying interactions with the S1' pocket. Metabolic stability was improved through reduction of inhibitor lipophilicity. This translated into lower in vivo clearance for the preferred compound. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.036
• 作为产物：
  描述：

  5-溴-2-糠酸 、 L-valine N-methylamide 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 5-bromo-furan-2-carboxylic acid ((S)-2-methyl-1-methylcarbamoyl-propyl)-amide
  参考文献：
  名称：

  SAR studies of non-zinc-chelating MMP-13 inhibitors: Improving selectivity and metabolic stability

  摘要：

  SAR studies to improve the selectivity and metabolic stability of a class of recently discovered MMP-13 inhibitors are reported. Improved selectivity was achieved by modifying interactions with the S1' pocket. Metabolic stability was improved through reduction of inhibitor lipophilicity. This translated into lower in vivo clearance for the preferred compound. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.036

文献信息

• Fused Heteroaryl Diamide Compounds Useful as MMP-13 Inhibitors
  申请人：Heim-Riether Alexander

  公开号：US20110269668A1

  公开（公告）日：2011-11-03

  Disclosed are compounds and compositions of the formula I as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula I.

  本发明涉及一种化合物和组合物，其化学式如下所述，该化合物和组合物是MMP-13的抑制剂。本发明还涉及使用和制备化合物的方法。
• FUSED HETEROARYL DIAMIDE COMPOUNDS USEFUL AS MMP-13 INHIBITORS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2344480A1

  公开（公告）日：2011-07-20
• SAR studies of non-zinc-chelating MMP-13 inhibitors: Improving selectivity and metabolic stability
  作者：Donghong Amy Gao、Zhaoming Xiong、Alexander Heim-Riether、Laura Amodeo、E. Michael August、Xianhua Cao、Leonard Ciccarelli、Brandon K. Collins、Kyle Harrington、Kathleen Haverty、Melissa Hill-Drzewi、Xiang Li、Shuang Liang、Steluta Mariana Margarit、Neil Moss、Nelamangala Nagaraja、John Proudfoot、Rene Roman、Sabine Schlyer、Lana Smith Keenan、Steven Taylor、Bernd Wellenzohn、Dieter Wiedenmayer、Jun Li、Neil A. Farrow

  DOI：10.1016/j.bmcl.2010.07.036

  日期：2010.9

  SAR studies to improve the selectivity and metabolic stability of a class of recently discovered MMP-13 inhibitors are reported. Improved selectivity was achieved by modifying interactions with the S1' pocket. Metabolic stability was improved through reduction of inhibitor lipophilicity. This translated into lower in vivo clearance for the preferred compound. (C) 2010 Elsevier Ltd. All rights reserved.